Neurotech

Neurotech Pharmaceuticals is a biotechnology company developing transformative, vision-saving therapies for chronic eye diseases. Its patented core technology platform, Encapsulated Cell Technology (ECT), is a genetically engineered implant that continuously delivers protein-based drugs directly into the vitreous of the eye over an extended period, eliminating the need for frequent injections or topical drops. Neurotech is currently conducting clinical research on its lead candidate product NT-501, including a Phase 3 clinical trial for the orphan disease Macular Telangiectasia (MacTel) and a Phase 2 clinical trial for glaucoma.